A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.

Nordica Fertility Clinic2,686 enrolled

Overview

To compare the effect of Crinone 8% administered once daily versus other vaginal progesterone in terms of ongoing pregnancy rate 5 weeks after embryo transfer as well as patient convenience.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

2,686

Conditions

IVF - Luteal Phase Support After Embryo Transfer

Interventions

progesteroneDRUG

90 mg, vaginal, once daily

ProgesteroneDRUG

200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-40 years * Regular menstrual cyclus 25-35 days * both ovaries present * No more than 2 previous IVF attempts * Have given written informed consent Exclusion Criteria: * More than 2 previous attempts * Known drug abuse * Known allergies to the study medication * No embryo transfer performed in the study cycle * Previous participating in the study

Locations (17)

Faurskov fertility clinic

Aalborg, Denmark

TERMINATED

Brædstrup Sygehus

Brædstrup, Denmark

Outcomes

Primary Outcomes

Equivalence in ongoing pregnancy per embryo transfer between the two groups

Time frame: week 5 after embryo tranfer

Secondary Outcomes

Convenience for the patient

Time frame: the treatment period (from the day of embryo transfer and 19 days ahead)

Central Contacts

Svend Lindenberg

CONTACT

004533257000 svend@lindenberg.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.